multiple sclerosis onset in adults, 447–450, 451–453t

sclerosis onset in children, 454–455

multiple sclerosis relapse in adults, 455–456

multiple sclerosis relapse in children, 457–458

neuromyelitis optica, 446–447

optic neuritis, 443–446

polyarteritis nodosa, onset or exacerbation, 477–479

psoriatic arthritis, onset or exacerbation, 479–480

reactive arthritis, onset or exacerbation, 480–482

rheumatoid arthritis, onset or exacerbation, 482–485

seizures, 438–440

summary of evidence and causality conclusions, 20t, 491–493t, 681–683t

systemic lupus erythematosus, onset or exacerbation, 471–473

transverse myelitis, 442–443

type 1 diabetes, 488–490

vasculitis, onset or exacerbation, 473–477

human papillomavirus vaccine

acute disseminated encephalomyelitis, 507–508

amyotrophic lateral sclerosis, 513–515

anaphylaxis, 515–516

brachial neuritis, 512–513

chronic inflammatory disseminated polyneuropathy, 512

Guillain-Barré syndrome, 511–512

hypercoagulable states, 520

multiple sclerosis, 510

neuromyelitis optica, 509

pancreatitis, 517–518

summary of evidence and causality conclusions, 21t, 521t, 683t

thromboembolic events, 519–520

transient arthralgia, 516–517

transverse myelitis, 508

influenza vaccine

acute disseminated encephalomyelitis, 308–309

all-cause mortality, 390–391

anaphylaxis, 341–345

arthropathy, onset or exacerbation, 384–385

asthma exacerbation or reactive airway disease episodes in children and adults, inactivated influenza vaccine, 345–356

asthma exacerbation or reactive airway disease episodes in children younger than 5 years of age, live attenuated influenza vaccine, 356–366

asthma exacerbation or reactive airway disease episodes in persons 5 years of age or older, live attenuated influenza vaccine, 366–373

Bell’s palsy, 335–337, 338–339t

brachial neuritis, 340

chronic inflammatory disseminated polyneuropathy, 334–335

encephalitis and encephalopathy, 296, 299–301

fibromyalgia, 389

Guillain-Barré syndrome, 321–334

multiple sclerosis onset in adults, 314–318

multiple sclerosis relapse in adults, 318–321

myocardial infarction, 387–389

neuromyelitis optica, 314

oculorespiratory syndrome, 391–401

optic neuritis, 310–313

polyarteritis nodosa, 383–384

seizures, 301–304, 305–307t

small fiber neuropathy, 340–341

stroke, 386–387

summary of evidence and causality conclusions, 20–22t, 402–404t, 678–680t

systemic lupus erythematosus, onset or exacerbation, 373–379

transverse myelitis, 309–310

vasculitis, onset or exacerbation, 379–383

injection-related adverse events

complex regional pain syndrome, 615–617

deltoid bursitis, 618–620

summary of evidence and causality conclusions, 21t, 625t, 687–688t,

syncope, 620–624



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement